<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), blasts constitutively activate the antiapoptotic transcription factor nuclear factor-kappaB (NF-kappaB) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we show that this NF-kappaB activation relies on the constitutive activation of the IkappaB kinase (IKK) complex, which is formed by the IKKalpha, IKKbeta and IKKgamma/NF-kappaB essential modulator (NEMO) subunits </plain></SENT>
<SENT sid="2" pm="."><plain>A cell-permeable <z:chebi fb="7" ids="16670">peptide</z:chebi> that mimics the leucine zipper subdomain of IKKgamma, thus preventing its oligomerization, inhibited the constitutive NF-kappaB activation and induced apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> in a panel of human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines (P39, MOLM13, THP1 and MV4-11) </plain></SENT>
<SENT sid="3" pm="."><plain>Small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi>-mediated knockdown of the p65 NF-kappaB subunit or the three IKK subunits including IKKgamma/NEMO also induced apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> in P39 cells </plain></SENT>
<SENT sid="4" pm="."><plain>Cell <z:hpo ids='HP_0011420'>death</z:hpo> induced by the IKKgamma/NEMO-antagonistic <z:chebi fb="7" ids="16670">peptide</z:chebi> involved the caspase-independent loss of the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> transmembrane potential as well as signs of outer <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane permeabilization with the consequent release of <z:chebi fb="1" ids="18070">cytochrome c</z:chebi>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing factor and endonuclease G </plain></SENT>
<SENT sid="5" pm="."><plain>Primary bone marrow CD34(+) cells from high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients also succumbed to the IKKgamma/NEMO-antagonistic <z:chebi fb="7" ids="16670">peptide</z:chebi>, but not to a mutated control <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Altogether, these data indicate that malignant cells in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells critically depend on IKKgamma/NEMO to survive </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, our data delineate a novel procedure for their therapeutic removal, through inhibition of IKKgamma/NEMO oligomerization </plain></SENT>
</text></document>